BioSpace News Archive

Immunic, Inc. announced the results of a pre-planned interim safety analysis and a recruitment update from the ongoing phase 2 CALVID-1 trial of its selective oral DHODH inhibitor, IMU-838, in patients with moderate coronavirus disease 2019.

In recognition of World Rabies Day on September 28, Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Kenilworth, N.J., USA, announced the launch of a global campaign to raise awareness among veterinarians, dog owners and volunteers who are committed to eliminate rabies through ongoing dog vaccination efforts.

The ehealth software and services market is rising at a stellar pace and is predicted to chart an impressive growth trajectory over the forecast period of 2019 to 2029.

The U.S. virtual visits market is likely to expand at an exponential growth rate during the forecast timeframe, from 2020 to 2029.

ILIAS Biologics Inc., a leading exosome-based therapeutics company, announced that the Company has completed a Series B financing round of $20.6 million in South Korea.

Koneksa will invest in the continued development of its digital platform for integrating wearables, sensors, and other technologies on a global scale.

AVROBIO, Inc., a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, announced that the European Commission has granted orphan drug designation for AVR-RD-02, the company’s investigational gene therapy for the treatment of Gaucher disease.

Economic and competitive pressures in the healthcare industry continue to motivate life sciences companies to explore ways of cutting costs across operations and increase their focus on product innovations, research activities, and improved turnaround time of deliverables.

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) provides an update on U.S. federal government and other funding options the Company is pursuing in order to advance its SARS-CoV-2 vaccine, Terra CoV-2. Oragenics has been informed by the Biomedical Advanced Research and Development Authority (“BARDA”) of BARDA’s determination not to enter into negotiation with the Company. While BARDA noted the Com

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present at Chardan’s Virtual 4 th Annual Genetic Medicines Conference on Monday, October 5, 2020 at 9 a.m. ET. A live webcast of Intellia’s presentation will be accessible through the Events and Presentations page of the Investors & Media section of the